Capital Impact Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Capital Impact Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,305	Closed	-$2.04M	–	124
2021 Q3	$2.04M	Sell	21,305 -3,191	-13%	-$301K	0.81%	57
2021 Q2	$2.38M	Buy	24,496 +9,759	+66%	+$935K	0.77%	59
2021 Q1	$1.43M	Sell	14,737 -7,369	-33%	-$773K	0.5%	73
2020 Q4	$2.12M	Hold	22,106	–	–	0.52%	76
2020 Q3	$2.13M	Hold	22,106	–	–	0.63%	75
2020 Q2	$2.7M	Hold	22,106	–	–	0.9%	42
2020 Q1	$1.91M	Buy	22,106 +943	+4%	+$92.3K	0.8%	54
2019 Q4	$2.27M	Buy	21,163 +2,614	+14%	+$274K	0.8%	48
2019 Q3	$1.67M	Sell	18,549 -2,374	-11%	-$222K	0.64%	100
2019 Q2	$1.72M	Buy	+20,923	New	+$1.72M	0.63%	86

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Impact Advisors's NBIX Position: Q4 2021 in Review

Capital Impact Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 21,305 shares — an estimated $2.04M sold.

Capital Impact Advisors first reported a position in NBIX in Q2 2019 and held it in 10 quarters. The position peaked at $2.7M in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

Capital Impact Advisors reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
Capital Impact Advisors sold 21,305 Neurocrine Biosciences shares in Q4 2021, an estimated $2.04M.
Capital Impact Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 10 quarters.
Capital Impact Advisors's Neurocrine Biosciences position peaked at $2.7M in Q2 2020.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Capital Impact Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.